24.02.2017 Captium Limited will lead the growth and expansion of Abionic products in the United Kingdom and Ireland. Physicians and pharmacists will get access to the most rapid allergy and iron deficiency blood tests.
Abionic SA, a developer of nanotechnology based point-of-care diagnostic solutions, announced today having signed an exclusive distribution agreement in the United Kingdom and Ireland with Captium Limited.
Allergic patients are grossly under-serviced in the United Kingdom and Ireland Abionic, with the requirement for only a small finger-prick blood sample is preferable to a big venous blood sample required for analysis laboratory measurements. Its ease of use and speed-to-results make the abioSCOPE the most adapted solution for providing patients with blood analysis results at the point-of-care.
Captium is a young company managed by the former Stallergenes SA General Manager for United Kingdom, Ireland and Canada, Kevin Wilkinson. Captium has expertise in allergy related medical products distribution and is aiming to provide medical practitioners with the highest quality products.
“Captium is a key distributor that maintains a close relationship with Opinion Leaders and especially with allergists across the United Kingdom and Ireland. It will contribute to reinforce Abionic strategic development in this market.” declared Dr. Nicolas Durand, founder and CEO of Abionic.
“We are delighted to have signed the partnership agreement as our presence and experience in those countries will enable the more than 20 million patients suffering from allergies and the millions with iron-deficiency diseases to have access to the benefits of Abionic technology”, declared Kevin Wilkinson, General Manager of Captium Limited.